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Overactive bladder syndrome (OAB) is defined 
by the International Continence Society (ICS) as 
urinary urgency, with or without urgent urinary 
incontinence, and often associated with urinary 
frequency and nocturia, in the absence of any 
pathological or metabolic conditions that may 
cause or mimic OAB.1 OAB treatment starts, 
according to guidelines, with behavioral therapy 
and if needed, is supplemented with drug 
treatment. When drug treatment is unsuccessful, 
the next line of treatment consists of percutane-
ous tibial nerve stimulation (PTNS) or intravesi-
cal Onabotulinum Toxin A injections or sacral 
nerve stimulation (SNS).2 Success rates of PTNS 
were described by Peters et al.3 in the first sham-
controlled trial for PTNS. They described an 
43% improvement for urinary urgency, 48% 
improvement for urinary frequency, 38% 
improvement for urge incontinence (UUI), and 
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Abstract
Introduction and objectives: Overactive bladder syndrome (OAB) is defined as urinary 
urgency, with or without urgent urinary incontinence; it is often associated with urinary 
frequency and nocturia, in the absence of any pathological or metabolic conditions that may 
cause or mimic OAB. The aim of this study was to evaluate the long-term real-life adherence 
of transcutaneous tibial nerve stimulation (TTNS) in the treatment of OAB, patient satisfaction 
of the treatment, and reasons for quitting therapy.
Materials and methods: In this single center study, all patients who had a positive effect on 
percutaneous tibial nerve stimulation (PTNS) and continued to receive home-based treatment 
with TTNS since 2012 were included for analysis. Patients were retrospectively asked to fill 
out a questionnaire regarding satisfaction, reasons for quitting, and additional or next line of 
therapy.
Results: We included 42 patients for this study, 81% of these patients were female (n = 34). 
The median age was 67 years (range 36–86). Most of the patients (64%, n = 27) were diagnosed 
with OAB wet. The median TTNS treatment persistence was 16 months (range 1–112 months). 
Reasons and percentages for stopping therapy were: 55% stopped treatment due to loss 
of effect, and 24% stopped because of preferring other type of neuromodulation. The mean 
satisfaction score (scale 1–10) in patients who continued TTNS was 6.2 (n = 9, SD 1.30) versus 
5.4 (n = 29, SD 2.24) for patients who quit therapy. We did not find a statistically significant 
difference between the two groups (p = 0.174).
Conclusion: TTNS, although effective in the short-term, is not effective in the long-term. In 
combination with a low satisfaction rate among patients, there is a need for improvement in 
terms of OAB treatment modalities.
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an overall improvement of 55%, based on the 
global response assessment (GRA) scale after 
13 weeks of treatment. However, one of the main 
disadvantages of PTNS is the fact that patients 
have to come to hospital for their treatment. 
Secondly, once PTNS treatment is quitted, 
patient’s complaints will return; therefore, 
patients will require maintenance therapy.4
Home-based treatment with transcutaneous stim-
ulation of the tibial nerve (TTNS) could solve 
these problems. TTNS uses a surface electrode, 
instead of a needle, to stimulate the tibial nerve, 
which can be self-applied by patients.5 Previous 
studies showed that TTNS in the study context is 
an effective treatment option in the treatment of 
idiopathic OAB.5–8 In particular, Ramírez-García 
et al.8 showed non-inferiority in the decrease of 
daytime frequency voiding in patients with idio-
pathic OAB and Detrusor Overactivity (DO) in 
their randomized controlled trial comparing PTNS 
versus TTNS. Both techniques improve symptoms 
and to a large extent, quality of life (QoL). 
Moreover, the perception of improvement did not 
differ between PTNS and TTNS. However, real-
life data related to efficacy and continuation of the 
treatment over the longer term are scarce.
The aim of this study was to evaluate the long-
term, real-life adherence of patients to TTNS for 
the treatment of OAB, including patient satisfac-
tion and reasons for stopping TTNS.
Material and methods
In this single center study, all patients who had 
positive effect on PTNS and who continued to 
receive home-based treatment with TTNS since 
2012 were included. Patients were retrospectively 
asked to fill out a questionnaire (supplementary 
data) regarding satisfaction, reasons for quitting, 
and additional or next line therapy. All patients 
were included in our single center university hos-
pital. All patients started with at least 7 treatment 
sessions of PTNS (median 18, range 7–49 weeks) 
once a week, followed by an evaluation session 
with their urologist. If there was a subjective 
improvement of their OAB complaints, patients 
were asked to continue to receive home-based 
TTNS treatment. Instructions for home-based 
TTNS were given by a specialized nurse and eval-
uation was performed two weeks after the start of 
TTNS therapy. During this follow up moment, it 
was evaluated if they required additional training. 
After this, patients continued to receive mainte-
nance therapy with TTNS at home, led by them-
selves, without any specific follow up.
Inclusions criteria for this study were patients 
with PTNS followed by TTNS. All patients who 
started PTNS and/or TTNS under the age of 18 
were excluded for analysis, as were patients with 
mental or physical limitations for filling out the 
questionnaire [i.e., Alzheimer’s, post cerebrovas-
cular accident (CVA) with physical limitations, 
illiterate]. Before the questionnaires were sent, 
patients were called to participate in the study. 
When patients could not be reached, they were 
defined as lost to follow up.
Baseline criteria and extra study details were 
retrieved from patient electronical files after receiv-
ing their informed consent. The questionnaire, 
which was sent to all patients, is included in the 
supplementary data. Statistical analysis was per-
formed by using SPSS 22.0 (SPSS, Chicago, IL). 
Kaplan–Meier curves were used to estimate the 
survival of TTNS. Discontinuation of TTNS was 
used as an endpoint. The T-test was performed to 
determine statistical significance between the mean 
satisfaction score (scale 1–10) of both patient 
groups: patients who continued the treatment ver-
sus patients who quitted treatment. This study was 
approved by the Ethics Committee of the Radboud 
University Nijmegen Medical Centre (2020-7035). 
Written informed consent was obtained from all 
patients for the use of clinical data in research.
Results
Baseline criteria
A total of 78 patients underwent PTNS followed 
by TTNS in our University Medical Center. 
Questionnaires were sent to 50 patients. The rea-
sons and numbers for not being included in the 
study were as follows: 15 patients were lost to fol-
low up, 6 patients had died, and 7 patients were 
determined to not be physically or mentally com-
petent to fill out the questionnaire. Out of our 50 
patients who met the inclusion and exclusion cri-
teria, 8 patients did not respond to our request to 
fill out the questionnaires. As a result, we included 
42 patients for this study (response rate intention 
to treat 55%, response rate per protocol 84%). 
Figure 1 shows the patient flow.
42 Patients were included; of these, 81% were 
female (n = 34). The median age was 67 years 
(range 36–86). Most of the patients (64%, n = 27) 
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were diagnosed with OAB wet, followed by OAB 
dry (19%, n = 8) and neurogenic origin (17% 
n = 7). A total of 67% (n = 28) of the included 
patients had previous medication and pelvic floor 
therapy, while 31% (n = 13) had medication only. 
For one patient it was unclear what treatment was 
received prior to the PTNS.
PTNS analysis
All patients received weekly PTNS sessions prior 
to their treatment with TTNS. The median dura-
tion of their PTNS treatment was 18 weeks (range 
7–49 weeks). We could not determine the dura-
tion of treatment for 3 patients, as these patients 
were treated in a hospital near their home instead 
of at our referral center.
TTNS analysis
All patients continued with TTNS after their 
PTNS treatment. The median TTNS treatment 
persistence was 16 months (ranges 1–112 months). 
Figure 2(a) illustrates the overall survival (OS) of 
TTNS treatment in all patients. Figure 2(b) illus-
trates the survival per category of OAB (OAB 
wet, OAB dry, and neurogenic origin). 
Unfortunately, due to the low numbers we could 
not perform any other statistical analysis. During 
treatment, 45% of the patients used TTNS on a 
daily basis, followed by 27.5% of the patients who 
were using it 3–6 times a week, and 22.5% who 
were using the system 1–2 times per week. Only a 
small percentage, 5%, used it less than once a 
week. Twenty-one percent continued treatment; 
reasons for and percentages for quitting therapy 
are shown in Figure 3. The main reason to dis-
continue TTNS was a loss of effect (55%).
During TTNS treatment, almost 62% of the 
patients did not use any other form of treatment, 
36% of the patients used medication as additional 
therapy, and in 2% it was unknown. The mean sat-
isfaction score (scale 1–10), for which all patients 
rated their TTNS treatment, was 5.6 [n = 38, 
standard deviation (SD) 2.07]. The mean treat-
ment score in patients who continued TTNS was 
6.2 (n = 9, SD 1.30) versus 5.4 (n = 29, SD 2.24) 
for patients who quit therapy. We did not find a 
statistically significant difference between the two 
groups (p = 0.174). If patients did stop TTNS, one 
third did not receive or continued with a different 
OAB treatment. When they opted for a different 
treatment, they mainly choose PTNS (21%), 
PTNS implant (18%), botox (12%), medication 
(9%), or sacral neuromodulation (6%).
Discussion
We report that, in this real-life study, the median 
treatment persistence of TTNS is only 16 months 
after start treatment. In addition, 55% of patients 
quit their therapy because of a loss of effect over 
time, while most of them were treating themselves 
on a daily base. These results illustrate the main 
short comings of TTNS over time. TTNS has a 
Figure 1. Study flow, patient inclusion/exclusion and number of patients final analysis.
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positive effect on OAB symptoms; this is shown 
for short term follow up by Booth in their sham 
controlled TTNS study, and Schreiner in their 
randomized controlled trial (RCT), where 
patients received TTNS in addition to standard 
therapy [bladder training, programme of repeated 
voluntary pelvic floor muscle contraction 
(PFMT)].9,10 Although TTNS is successful at the 
start, we observed that most patients do not con-
tinue with their treatment in the long term due to 
the numerous reasons provided above.
If we compare our real-life data regarding the 
long-term treatment efficacy to existing studies, 
we do see slightly different outcomes. Leroux 
et al.7 describe in their study a mean TTNS per-
sistence of 8.3 months: 29% of their patients con-
tinued for over 12 months. Only 16% continued 
for 18 months or more, compared to our median 
follow up of 16 months. Only 17% of their patients 
continued treatment with TTNS during their end 
of study moment; on contrast, we found this fig-
ure to be 21%. The reasons for this difference 
could be explained by the number of patients 
included in both studies, but also by the differ-
ences in design of both studies. However, it can 
be concluded that the results from both studies 
show that TTNS treatment persistence is cur-
rently not satisfactory.
Comparing our long-term TTNS therapy adher-
ence data to real-life PTNS data, we do not see a 
large difference in outcome. As previously dis-
cussed, the median treatment persistence in our 
study was 16 months (n = 42). In real-life PTNS 
studies (n = 183) the median follow up of patients 
during maintenance treatment is 18 months.11 
Sirls et al.12 describe in their real-world study that 
55% of their patients continued maintenance 
PTNS treatment after 3 months. However, the 
reasons for discontinuation of PTNS differ from 
TTNS, mainly because of the logistic intensity 
(frequent clinical visits) of the PTNS treatment 
compared to TTNS.11
Figure 3. Reasons for discontinuation of TTNS (N = 33).
TTNS, transcutaneous stimulation of the tibial nerve
Figure 2. (a) Treatment duration of TTNS in months among all patients (n = 42) (b) Treatment duration of TTNS in months specified 
per category (OAB wet n = 26, OAB dry n = 8, neurogenic n = 7).
OAB, overactive bladder syndrome; TTNS, transcutaneous stimulation of the tibial nerve.
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The main reason for TTNS discontinuation was 
a loss of efficacy or a lack of sufficient symptom 
relief. This is in line with other publications. 
Leroux describes that 70% of their patients 
stopped treatment due to a lack of sufficient 
symptom relief.7 They further mentioned compli-
ance difficulty and becoming asymptomatic as 
reasons for discontinuation. This could be the 
reason why, in their series, 70% of patients expe-
rienced a loss of effect; this is higher compared to 
the 55% in our study.
In this study we could only quantify the level of 
satisfaction rate of patients by recall for both treat-
ment periods with PTNS and TTNS. Patients 
rated their TTNS treatment generally, with an 
overall 5.6 (scale 1–10) report grade. This fairly 
low score, in addition to the fact that patients 
often preferred a different form of TNM (24%) 
suggests that other forms of TNM had more satis-
factory outcomes. These observations are in con-
trast to a RCT published by Martin Garcia 
followed by a non-inferiority study by Ramírez-
García.6,8 Both studies concluded that there was 
no statistical difference in efficacy outcome and 
QoL questionnaires in TTNS versus PTNS.
Posterior tibial neuromodulation, and as a part of 
this TTNS, has proven its efficacy over the years 
in the treatment of OAB.3,9,13 However, similar to 
other OAB treatment modalities, long term ther-
apy adherence is poor and alternative treatment 
options are scarce. For the most part, OAB 
patients stop these forms of therapy because of 
side effects or a lack of efficacy in the longer-
term.11,14 In our view, this is also the case for 
TTNS in the real-life setting. The limitations of 
our study are the number of patients which were 
included and the single center nature of the study. 
As shown in Figure 2(b), there could be some dif-
ferences between OAB categories. However, our 
numbers were too low and this poses a limitation 
on reaching a solid conclusion. We hope that a 
more patient tailored, minimally-invasive treat-
ment modality could enhance persistence and 
adherence for patients utilizing the current OAB 
treatment modalities in the future. As a result, 
developments in the efficacy of tibial nerve stimu-
lation utilizing implantable devices is, therefore, 
of interest.15–17
Conclusion
Although many publications report a positive 
effect of TTNS on patients suffering from OAB in 
short term follow up, TTNS in the long term is 
not that effective in real-life. In combination with 
a low satisfaction rate, the need for other OAB 
treatments is still persistent. In order to appreciate 
the value of treatment modalities, also for OAB, 
more research in the real-world setting is needed.
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